Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update • Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 • Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectively • IND submis ...

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist; reiterating top-line data anticipated by mid 2025 and H1 2026, respectivelyIND submissions for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 an ...

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flareOf the remaining eight responding patients from GEMINI-1 re-randomized to placebo in GEMINI-2, 25% maintained clear to almost clear skin and 63% of these patients experienced a flareSafety and tolerability in GEMINI- ...

AnaptysBio, Inc. (ANAB) shares soared 14.3% in the last trading session to close at $24.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.1% loss over the past four weeks.The company is currently developing a robust portfolio of immune cell modulators, including two checkpoint agonists and a BTLA agonist, which are currently being evaluated in various mid-stage studies for the treatment of several autoimmune and inflammatory ...

BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym ...

The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro Computer (NASDAQ:SMCI) leading the way with a 216% gain so far.However, analysts at the wealth management arm of Goldman Sachs think the tech sector may have run its course. They say it is time to start looking elsewhere. Investors would be better off taking the profits they’ve made in tech and deploying them ...

A powerfully bullish new analyst take on the company helped it rally on the market.Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (ANAB -8.17%). The company's shares closed the week almost 8% higher in price, according to data compiled by S&P Global Market Intelligence, largely on the strength of a research note published by a high-profile and influential bank.Doing well by Wells FargoThat occurred on Thursday before market open, when Wells Fargo initi ...

ANAB Quick Quote - One stock that might be an intriguing choice for investors right now is AnaptysBio ( Free Report ) . This is because this security in the Medical-Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is ...

AnaptysBio, Inc. (ANAB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing e ...

AnaptysBio, Inc. (ANAB) closed the last trading session at $24.69, gaining 10.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.88 indicates a 69.6% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $20.07. While the lowest estimate of $20 indicates a 19% decline from the current price level, the most optimistic analyst ex ...